RE:RE:RE:Is MDNA holding TLT back? TLT`s small Trial will be about more than demonstrating superior efficacy - it should be definitive proof of concept for the elegance and superiority of PDT as a treatment modality.
Worth looking at Medicenna`s complex and invasive mechanism of drug delivery from their presentation of the 20th of November 2019 (see details below). They can exert beneficial influence and extend life expectancy in respect of those 76% of GBM tumours that over-express IL-4 but this does not eliminate the tumours and such delivery begs the question as to whether such treatment could be repeated?
Rutherrin on the other hand can be intravenously administered to find its`way across the blood-brain barrier to selectively accumulate in the tumour. Might it then be activated trans-cranially - i.e. a entirely non-invasive treatment??? That is a big question to which we haven’t yet been told the answer.
EVENTS AND PRESENTATIONS
24th Annual Meeting of the Society of Neuro-Oncology and 3rd Joint Conference of SNO and Society for CNS Interstitial Delivery of Therapeutics
Wednesday, November 20, 2019
3:10pm MST
Convection-Enhanced Delivery (CED) of MDNA55 in Adults with Recurrent Glioblastoma
Presenter: Dr. Nicholas Butowski, MD – Professor of Neurological Surgery and Director of Translational Research in Neuro-Oncology at The Helen Diller Family Comprehensive Cancer Center, University of California San Francisco
Room: Grand Saguaro East
Download Presentation
6.1 MB